CerebraCell Unveils “Brain Saving” Helmet for Rapid Stroke Recovery

bio Unknow2nAugust 5th, 2016 – Santa Monica, CA and Salt Lake City, UT – CerebraCell a Leonhardt Ventures Co. released today that it has filed a provisional patent application for a “brain saving” helmet to help minimize the damage from strokes.  Here is a link to a video demonstration of the technology –https://vimeo.com/175899331  The company envisions that every ambulance will have these devices in the future and they will be stored in airports, planes, malls, stadiums and other high people traffic areas just like portable defibrillators are today.   The CerebraCell “brain saving” helmet is equipped with a bioelectric energy micro stimulator that controls release of 10 key brain regeneration and brain blood flow promoting proteins including SDF-1, a stem cell homing signal and IGF-1 (DNA repair molecule).  The helmet is equipped with bioelectric signal transmitting micro electroacupuncture electrodes that either transcutaneously or percutaneously contacts safely scalp tissue.   A micro infusion pump is included that may be repeatedly loaded with the CCA-15 and/or CCR-15 CerebraCell proprietary fifteen component stem cell based angiogenic and regeneration compositions.  EMT personnel will carry frozen syringes with these compositions pre-loaded and ready to inject just as they do today for rapid clot dissolving drugs.  In stroke management time = brain.  So if this auto programmed helmet can be placed on a stroke victims head as soon as possible after artery blockage and clot dissolving we believe we can preserve much greater amount of brain tissue from the damaging effects of the stroke.  Earlier this week the CerebraCell team announced a joint venture with HeartScore.co, the disease management company, to co-develop in partnership with other firms a comprehensive tele-stroke management and recovery program which will include the CerebraCell auto programmed “brain saving” helmet –http://mysocialgoodnews.com/heartscore-co-cerebracell-announce-joint-venture-tele-stroke-management-recovery/.  This helmet is being designed so that any EMT personnel under the remote tele-conferencing guidance of a physician can apply the “brain saving” therapy within minutes of arrival to the patient’s home or other location of stroke onset. 

CerebraCell is implementing a carefully designed translational study plan with patient safety in mind first.  It is our hope that this product will enter clinical trials in 2017.  The Leonhardt Ventures team that guides CerebraCell has significant experience in implementing organ regeneration and repair clinical studies since the 1980’s. The team completed the first-in-man pioneering percutaneous stent graft aortic aneurysm repair case in 1995 in Melbourne, Australia that led onto pilot, Phase I, Phase II and Phase III studies that have established the Leonhardt patented stent graft still today holding a world leading share of all non-surgical aortic aneurysm repairs.  In early 2001 the team led the historic first-in-man percutaneous muscle stem cell repair of a damaged heart in The Netherlands that led onto successful pilot, Phase I, Phase II and Phase II/III studies.  

About CerebraCell:

CerebraCell formed in 2015 is focused on brain regeneration utilizing bioelectric stimulation and and a re-fillable micro infusion pump that is re-filled daily or weekly with the CCA-15 or CCR-15 angiogenic and regeneration mixed stem cell based compositions.  For more information including supporting scientific articles please visit http://leonhardtventures.com/cerebracell/

About Leonhardt Ventures:

Leonhardt Ventures formed in 1982 as H.J. Leonhardt & Co. pioneered compliant balloon cardiovascular catheters, electrical stimulation for improving blood flow and turn key caths labs in the 1980s, intravascular lung, radiation caths, stem cell delivery systems, stent grafts, percutaneous heart valve and stem cell repair of hearts in the 1990’s.   Since 2000 the team has focused on bioelectric + stem cell based organ regeneration, circulatory assist devices and genomics and high fidelity data based heart failure and stroke management and recovery.  Leonhardt Ventues operates incubators and accelerators in California and Utah to primarily move its own inventions from concept to market as well as a select few from outside its own laboratories.  See www.leonhardtventures.com for more information. 

Contact:  Howard Leonhardt, email hleonhardt@aol.com, Leonhardt’s Launchpads Utah, 489E 400 South, Unit 116, Salt Lake City UT or Leonhardt Ventures, 1531 6th Street, Unit 401, Santa Monica, CA  90401

Device to Cut Orthodontic Treatment Time in Half – Leonhardt Ventures and OrthodontiCell File Provisional Patent Application

Santa Monica, CA and Salt Lake City, Utah, April. 20th, 2016 – PRBuzz – Leonhardt Ventures — a developer, manufacturer and marketer of advanced organ regeneration products — has announced the expansion of its intellectual property portfolio via its startup OrthodontiCell.  OrthodontiCell is incubating within Cal-X Stars Business Accelerator, Inc.  The Company has filed a provisional patent application in the U.S. Patent and Trademark Office for inventions relating to bioelectric stimulation controlled release of RANKL and a number of other proteins, including stem cell homing factor SDF-1, designed to accelerate tooth movement and cut in half the time required for orthodontic treatment with braces and clear aligners – the OrthodontiCell Tooth Movement Accelerator TM.  Studies are currently underway in Argentina.

Howard J. Leonhardt the Founder and CEO of Leonhardt, Ventures and Cal-X Stars Business Accelerator, Inc., Dr. John Marchetto an Orthodontist in Weston, Florida and Dr. Jorge Genovese a collaborative researcher from Buenos Aires, Argentina are co-inventors of this product.
“This invention addresses the desire to reduce in half the time it takes to treat orthodontic patients.  The approach is  to speed up the normal process of bone demineralization in order to accelerate tooth movement.  Millions of people that wear braces or aligners would love to cut their treatment time in half.  Other light and vibration devices fall short in providing a clear and reliable pathway to the underlying mechanism of action for tooth movement.  Also, the repeat RANKL needle injection methods are painful for the patients and are needed too frequently.  This invention is completely different than previous devices as it provides clear cut direct control for the release of essential cells and proteins needed for accelerating tooth movement, and with less pain”,  states Dr. John Marchetto, co-Inventor.

The OrthodontiCell team is in the process of launching well-designed studies both in and outside the U.S. to document the safety and efficacy of its Tooth Movement Accelerator TM product.

 

Howard Leonhardt co-inventor of this device previously patented an electrical stimulation device for recruiting stem cells to damaged organs including the heart by causing the release of SDF-1 stromal derived factor-1 on demand working in collaboration with Dr. Juan Chachques of Paris – http://www.google.com/patents/US20050171578.  Dr. Genovese has been conducting electrical stimulation based regeneration research for over twenty years with numerous published peer reviewed papers and is co-inventor with Leonhardt on nearly a dozen new patents pending.
Howard Leonhardt presented earlier this year their team’s 27 Year Experience with Stem Cell Therapies for Organ Regeneration and highlighted some of the spin out startup technology platforms that have emerged from the original work on heart regeneration which are now also incubating in the Cal-X Stars Business Accelerator and Leonhardt’s Launchpads – http://mysocialgoodnews.com/howard-leonhardt-to-present-27-years-of-experience-with-stem-cell-therapies-at-academy-of-regenerative-practices-winter-conference-and-scientific-seminar/

About Leonhardt Ventures:   Since 1982 Leonhardt Ventures (formerly H.J. Leonhardt & Co.) has been developing and bringing to market cardiovascular products.  Howard Leonhardt founder has 21 issued U.S. patents with over 100 U.S. patent claims and has about a dozen more pending or in process.   Leading past products include the POLY-CATH line of predictably compliant balloon catheters, TALENT stent graft, VALVE STENT percutaneous heart valve, MyoCath and Pro-Cell Stem Cell Delivery Catheters, BioPace biological pacemaker, Stem Cell Bra and the BioLeonhardt micro stimulator and micro pump for heart regeneration – www.leonhardtventures.com

About Cal-X Stars Business Accelerator, Inc.:   Formed in 2012 Cal-X Stars is a 5 year business accelerator focused on regenerative medtech and regenerative economy startups.   Cal-X Stars Business Accelerator, Inc. helps support and operate Leonhardt’s Launchpads NorCal, CalXelerator, SciAcclerator, Leonhardt’s Launchpads Utah, LABioHub and Startup California – www.calxstars.com

About OrthodontiCell:  A startup focused on accelerating tooth movement formed in 2015 by Dr. John Marchetto and Howard Leonhardt incubating within the Cal-X Stars Business Accelerator.  A spin out of previously formed DentaCell.

About DentaCell:  A startup focused on reducing pain and accelerating healing of gums after dental procedures and on tooth pulp cold storage for later stem cell retrieval and expansion founded incubating with the Cal-X Stars Business Accelerator – http://leonhardtventures.com/dentacell/

All capital for OrthodontiCell (a high risk early stage startup) is raised only through Cal-X Stars Business Accelerator, Inc via 506D Part C – SEE RISK FACTORS HERE >http://calxstars.com/investor-relations/ limited to accredited and sophisticated investors only or Leonhardt Ventures’s own internal funds at this time.   Leonhardt Ventures and Cal-X Stars Business Accelerator, Inc. are incubating 23 regenerative medtech startups at this time most of them based on the same patented micro stimulator and micro pump combination device pointed to different organs – BioLeonhardt MyoStim = heart, MyoStim Peripheral = limbs, CerebraCell = brain, EyeCell = eye, AortaCell = aortas, PancreaCell = pancreas, Stem Cell Bra = breast, RegenaLung = lungs, HairCell = hair, Valvublator = heart valves, BioPace = biological pacemaker.

Leonhardt Ventures’ Cal-X Stars Business Accelerator is led by over 70 business mentors and team members with substantial industry experience – http://calxstars.com/team-cal-x/and over 35 scientists and clinicians on our Scientific Advisory Board – http://calxstars.com/scientific-advisory-board/

Contact:  OrthodontiCell a Cal-X Stars Business Accelerator, Inc. Startup Technology Platform –  Media Relations Brian Hardy @   brian@fizzpopmedia.com or Howard Leonhardt @   hleonhardt@aol.com.
This provisional patent application was filed electronically utilizing www.legalzoom.com software.

Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the “safe harbor” created by those sections. All statements in this release that are not based on historical fact are “forward looking statements.” These statements may be identified by words such as “estimates,” “anticipates,” “projects,” “plans,” “proposes” or “planned,” “seeks,” “may,” “will,” “expects,” “intends,” “believes,” “should,” “would,” “could” and similar expressions or the negative versions thereof and which also may be identified by their context, such as references to “products under development”. All statements that address operating performance or events or developments that Cal-X Stars Business Accelerator, Inc. or any of its incubating startups such as BioLeonhardt MyoStim, DentalCell or OrthdontiCell, expects or anticipates will occur in the future are forward-looking statements. While management has based any forward looking statements included in this release on its current expectations, we operate in a complex and changing domestic and international competitive environment where new and unanticipated risks may arise, and consequently the information on which such expectations were based, such as expectations of distributor product placements and sales, timing of planned and anticipated product deliveries or product introductions, may change. Forward-looking statements involve inherent very high risks and multiple uncertainties which could cause actual results to differ materially from those in the forward-looking statements as a result of various factors, including those risks and uncertainties described in the Risk Factors and in Management’s Discussion of the Company’s filed Private Placement Memorandum.  We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.  The information shared communicates our intent of direction but does not imply in any form that any required agreements, patents are locked secure in place.  All our incubating startups are under funded and under staffed and we are bootstrapping to make progress with limited resources. We are at even greater risk due to our business plan of bringing multiple startups forward simultaneously with a small core staff spread thin.  Cal-X Stars Business Accelerator, Inc. incubates early stage startups and technology platforms focused on regenerative medtech and regenerative economy innovations.  By nature these early stage startups are high risk investments compounded in risk by requiring many years to get to market through clinical trials and multiple collaborative agreements which are not yet secured.  This investment is only suitable to sophisticated and accredited investors prepared to lose all of their investment understanding clearly the very high risk.

Leonhardt Ventures and CerebraCell File Patent Application for BioElectric Signals to Halt Tumor Growth and Regenerate Organs

– Signals for stopping cell division and halting blood flow to tumors followed by full regeneration program –

logoleonhardtventures1460646606

Press Release – Santa Monica, CA and Salt Lake City, UT – April 14th, 2016 – Leonhardt Ventures and its spin out startups CerebraCell, PancreaCell, RegenaLung and CancerCell are pleased to announce they have filed a provisional patent application with over 30 patent invention claims with the U.S. Patent and Trademark Office (USPTO) for its first cancer focused therapy comprising signals of halting cell division, stopping blood supply to tumors then followed by a full comprehensive program for organ regeneration.

The patent application is entitled “Treating Cancer Tumors Using BioElectric Stimulation in Combination with Micro Infusion” Inventors Howard J. Leonhardt and Jorge Genovese. This technology is based on bioelectric signals delivered via a micro stimulator device the size of a quarter. The signals may be delivered to target tumors and tissues via non-invasive means via a wearable brain cap or via wireless transmission. When desired a small wire probe may be directed precisely to the tumor and the tissue area targeted for regeneration after cancer treatment. The device may be used as a stimulator alone for small tumors with a small amount of associated organ damage and in combination with a micro infusion pump in cases of large or multiple tumors and significant organ damage in need of regeneration. Although the optimal and desired cancer tumor treatment regime is free of tissue damaging and side effect riddle chemo therapy or radiation it may be used in conjunction with those treatment options when deemed best for the patient by their physician. The regeneration protocol is also predicted to be useful for recovering from these treatment modalities as well and it is hoped that the bioelectric stimulation signaling can reduce the need for chemo or radiation and in many cases eliminate totally the need for these more toxic treatments.

“We do not claim in any way to have an easy instant cure for cancer yet but we are sharing that while we studied organ regeneration targeted bioelectric signals intended to promote controlled cell proliferation and controlled new blood vessel growth we stumbled across signals that seem to promptly stop cell division and blood supply. We decided to file with the USPTO these new inventions with the purpose of stopping cancer tumor growth and combine them our existing portfolio of organ regeneration technologies. The next step will be carefully designed studies to prove out the combination with the hope for complete cancer recovery with less side effects compared to currently available treatments.” states co-inventor Howard J. Leonhardt

“What is unique about this invention is the combination of stopping cell division and stopping blood supply, presumably without toxic side effects found from chemo and radiation treatments, followed by a complete organ regeneration protocol. Other cancer treatments are both toxic and incomplete in fully recovering a patient back to a high quality of life.” states co-inventor Dr. Jorge Genovese “We have high hope for this technology to make a major difference for the better in treating cancer patients and we are on the research path now to prove this out with well controlled studies.” Genovese further states.

Leonhardt-Genovese Patent Abstract

Cytokine + Chemotherapeutic and regenerative treatment for certain cancers may be combined with low intensity, intermediate frequency alternating electric fields that are tuned to release specific beneficial proteins at specific time intervals. More specifically, cell proliferation inhibition and halting blood supply to tumors in the first treatment stage. The bioelectric stimulation treatment may be increased in volume and efficacy by the combination use of an implantable, programmable, re-fillable micro infusion pump that delivers anti-cell proliferation and anti-blood vessel growth proteins as well, if desired, standard cancer treatment drugs such as chemo therapy agents. The second stage of treatment is focused regeneration of cancer damaged tissues back to their most optimal healthy state. The regenerative phase comprises a sequence of recruiting repairative stem cells to the damaged organ by bioelectrically stimulating the the release of SDF-1 (stem cell homing factor), followed by a controlled proliferation signal, a controlled blood vessel supply signal (VEGF) and if desired and useful release of Follistatin, Tropinelastin, Hepatocyte Growth Factor, IGF-1, eNOS and Activin. The stimulation cycle causing release of beneficial proteins for regeneration may be upgraded in volume and speed of delivery by the combination use of an implantable, re-fillable, programmable micro infusion pump for delivering a higher quantity of stem cells, nutrient hydrogel, matrix and other beneficial tissue and organ regeneration promotion proteins.

SUMMARY OF THE INVENTION

Cytokine + Chemotherapeutic and regenerative treatment for certain cancers comprising a combination low intensity, intermediate frequency alternating electric fields that are tuned to release particular beneficial proteins in two stages, stage (1) = stopping cancer spread by halting cell proliferation and halting tumor blood supply and stage (2) regenerating the cancer damaged tissue or organ back to optimal health. In many cases, the resulting cell proliferation inhibition is expected to be significantly higher than the inhibition obtained by drug-only regimens of treatment.

A method of killing or inhibiting the growth of cancer cells in a target region followed by regenerating the tissue or organ back to optimal health, the method comprising the steps of:

Stage 1 = Stop cancer tumor growth

applying, to the target region, a series of bioelectric signals that damages the cancer cells or inhibits the growth of the cancer cells via stopping cell proliferation and halting blood supply temporarily, but leaves normal cells in the target region substantially unharmed; and
treating the cancer cells with an other anti-cancer regimen via programmable micro pump infusion, wherein the applying step and the treating step are performed simultaneously.

Stage 2 = Regeneration of post cancer tissue or organ

treating the target region with a series of bioelectric signals to recruit stem cells, grow healthy blood vessels and re-grow healthy functional tissues in the previous cancer damaged region.

Leonhardt Ventures is interested in partnership opportunities for its proprietary technology platform with other biotechnology /pharmaceutical companies. Additionally, CerebraCell, PancreaCell and Regenalung, Leonhardt Ventures spin out startups, are exploring collaboration opportunities with investigators and clinical sites for potential combination treatment options for brain, pancreas and lung cancers indications respectively. The IP portfolio for all other potential cancer treatment indications of use will be housed in a new Leonhardt Ventures spin out startup to be incubated within the Cal-X Stars Business Accelerator, Inc. called CancerCell including breast, skin, prostrate, throat, colon, cervical, throat and esophagus cancers.

Note – CerebraCell is dually incubating in the Cal-X Stars Business Accelerator in Santa Monica and at the University of Northern California Science and Technology Innovation Center in Rohnert Park, CA under the guidance of over 70 business mentors and 35 scientific advisory board members. PancreaCell, RegenaLung and CancerCell are dually incubating in the Cal-X Stars Business Accelerator in Santa Monica and the newly formed Leonhardt’s Launchpads Utah incubator/incubator in Salt Lake City.

About Leonhardt Ventures: Leonhardt Ventures since 1982 (formerly HJ Leonhardt & Co.) has been leading the development of products for treating cardiovascular and heart disease. Operating since 2005 as Leonhardt Vineyards LLC DBA Leonhardt Ventures a California C corporation – www.leonhardtventures.com. In the 1980’s the team led the development of turn-key cardiac cath labs, blood oxygenators, heart valves, electrical stimulation devices for improving blood flow and patented predictably compliant balloon cardiovascular catheters. In the 1990s percutaneous heart valves, stem cell delivery catheters, biological pacing, radiation delivery catheters, intravascular lung, heart valve decalcification, endovascular stent grafts and stem cell repair of hearts. From 2000 forward the primary focus has been on organ regeneration research by the the combination of stem cell delivery, now via a micro pump, and programmed bioelectric stimulation release of specific regeneration proteins led by its flagship startup BioLeonhardt MyoStimwww.bioleonhardt.com + www.myostimpacers.com

About Cal-X Stars Business Accelerator, Inc: Formed in 2012 and incorporated as a C corporation in California in 2013 Cal-X Stars is a 5 year business accelerator focused on regenerative medtech and regenerative economy startups and innovations –www.calxstars.com. Most of the inventions that are the foundation of the startups within the accelerator come from Leonhardt Ventures own associated research centers- www.leonhardtventures.com Cal-X Stars Business Accelerator, Inc. helps operate and support Cal-Xelerator www.calxelerator.com a 108 day startup launch accelerator, Leonhardt’s Launchapds NorCalwww.leonhardtslaunchpads.com a life science incubator (founded 2007), Startup California http://startupcalifornia.org a startup launch assistance resource, LABiohub www.labiohub.org a life science startup assistance resource focused on the Los Angeles region and Leonhardt’s Launchpads Utah focused on helping launch life science and regenerative economy startups in Utah.

Leonhardt Ventures and the Cal-X Stars Business Accelerator are supported by 35 person Scientific Advisory Board –http://calxstars.com/scientific-advisory-board/ and a 73 person Business Advisory and Mentorship Board – http://calxstars.com/team-cal-x/ that help guide all of their associated startups and licensable technology platforms.

Reader Advisory

Statements in this press release may contain forward – looking information. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward looking statements. Forward – looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expects” and similar expressions. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward – looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward – looking statements contained in this press release are expressly qualified by this cautionary statement. The forward – looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by securities law. Any investment in Cal-X Stars Business Accelerator, Inc. and its associated startups must be deemed extremely high risk due to the early nature of the research, the high costs to bring products to market in this sector, the undercapitalized and understaffed nature of the business model, the high risk of patent and product liability law suits and a multitude of other risks including lack of single focus of the organization and the use of shared resources not fully controlled by the startups or the accelerator. Investment opportunity is limited to experienced accredited investors only able to bear full loss. Refer to all RISKS found on our investor relations page and links – http://calxstars.com/investor-relations/

Link To Original Story: https://www.prbuzz.com/business-entrepreneur/372501-leonhardt-ventures-and-cerebracell-file-patent-application-for-bioelectric-signals-to-halt-tumor-growth-and-regenerate-organs.html

IGF-1 Controlled Release by Bioelectric Stimulation Provisional Patent Filed by Leonhardt Ventures

Leonhardt Ventures, CerebraCell & BioLeonhardt File Provisional Patent Application For Electrical Stimulation Controlled Release of IGF-1

Key Tool in Regenerating Brains, Hearts, Eyes, Livers, Kidneys, Breasts, Lungs, Pancreas, Skin, Aortas, Heart Valves, Joints, Limbs and Arteries 

Santa Monica, CA and Salt Lake City, Utah , April 1st, 2016 – /PRBuzz- BioLeonhardt MyoStim www.bioleonhardt.com and CerebraCell both founded by Leonhardt Ventures www.leonhardtventures.com a developer, manufacturer and marketer of advanced organ regeneration products has announced the expansion of their intellectual property portfolios. BioLeonhardt MyoStim and CerebraCell are incubating within the Cal-X Stars Business Accelerator, Inc. www.calxstars.com. CerebraCell is dually incuating at the University of Northern California Science and Technology Center (UNC STIC) http://www.uncm.edu/STIC.php. The startups via Leonhardt Ventures have filed a provisional patent application with the U.S. Patent and Trademark Office for invention claims relating to bioelectric stimulation controlled release of IGF-1 a powerful cell, tissue and complete organ regeneration growth factor with a special focus on heart and brain regeneration but with applicability to a wide range of other organs and tissues.

Howard J. Leonhardt the Founder and CEO of Leonhardt Ventures, Cerebracell and BioLeonhardt MyoStim and Dr. Jorge Genovese a collaborative researcher from Buenos Aires, Argentina are co-inventors of this product. Howard Leonhardt previously patented a series of electrical stimulation devices and signals for homing stem cells to targeted tissues and the controlled differentiation when required into contractile muscle, even within scar tissue, starting back starting back in 2000. Dr. Genovese has been conducting electrical stimulation based regeneration research for over twenty years with numerous published peer reviewed papers.

Two Entities Seek to Collaborate to Grow Bioscience Startups into Thriving Businesses

Two Entities Seek to Collaborate to Grow Bioscience Startups into Thriving Businesses

 

Los Angeles, California – LABioHub, the Los Angeles-based consortium dedicated to aiding the growth of biomedical enterprises in the region, announced this morning their working partnership with RedSky, the for-profit subsidiary of the Medical Center of the Americas Foundation, based in El Paso, Texas where they engage area researchers and companies in the incubation, acceleration, and commercialization of revolutionary medical devices and medicines.

 

RedSky is bringing new energy to the biomedical research startup world, with its launch of a Seed Accelerator program that provides up to $200,000 per year in seed capital for six to 10 teams or startups over a three-month period to develop novel technologies that will drive medical progress and economic growth. As participants in the RedSky Seed Accelerator, each team will receive up to $20,000 for early development costs in exchange for up to 7 percent equity in the company or company to be formed. Additional perks to RedSky’s Seed Accelerator program include legal and accounting services, office space, a robust entrepreneurship curriculum, business advisory services and executive coaching from the Redsky team, and dedicated mentors, culminating in a Demo Day.

 

LABioHub has lined up over 100 mentors and scientific advisory board members comprised of world leaders in the life sciences and industry, and has developed bridges of relations to bioscience startup development resources in the region – a base that LABioHub builds on every day. RedSky is doing the same, not only in the Paso del Norte region (West Texas, Southern New Mexico, and Northern State of Chihuahua in Mexico), but also nationally and internationally. Both organizations realize that game-changing innovation is best attained through collaboration.

 

This collaboration partnership provides both companies with the opportunity to establish a hub in the highly fragmented biomedical innovations market by leaning on each other’s strengths to become stronger together. Some examples include:

 

LABioHub will help RedSky startups to:

  • Develop high-emotional impact videos that help tell their story. Los Angeles is a leader in crafted well told on video.
  • Develop successful crowdfunding campaigns.
  • Provide introductions to researchers and clinical investigators at UCLA, USC, Cal-Tech, Cedars Sinai, Huntington and other leading Los Angeles area centers.
  • Coordinate introductions, when appropriate, to the industry leaders in the Los Angeles area such as Amgen, Alfred Mann and Nantworks.

 

RedSky will help LABioHub startups to:

  • Conduct market analysis and develop marketing plans backed with solid supporting data.
  • Facilitate introductions to a network of clinical investigators and research collaborators for trials including Mexico.
  • Arrange introductions to the resources of the Paso del Norte region, and Texas-based industry leaders.

 

As part of the collaborative agreement, each entity will agree to host visitor members at their respective sites that are on missions to find collaborative researchers or capital, and to help arrange Demo Days in their respective states, attracting investors. Useful seminars held at either location will be live-streamed or video-recorded for viewing at the other respective site.

 

“In the modern noisy marketplace, it is hard to be heard above the crowd especially for a startup. You may have a great product or service but if no one knows about it, you are not going to go far. In today’s world, all companies are media companies whether they like it or not. A company IS its network. With this alliance we hope to grow our ability to help bioscience startups with introductions, network building and media outreach which is essential for success,” comments Howard J. Leonhardt of Leonhardt Ventures and Co-Founder of LABioHub.

 

Richard Koffler, CEO of the medtech device incubator Greenwings Biomedical and co-founder of LA BioHub remarks, “The partnership with RedSky is perfectly aligned with LA BioHub’s mission of providing LA’s life-science startups with the tools, knowledge and inspiration they need to make rapid progress. RedSky brings a portfolio of very valuable professional services and connections, and we give them direct access to one of the world’s fastest growing regions in life-science innovation.”

“This networking collaboration is a clear case of one plus one is three instead of two.  By leveraging each other strengths and network of potential introductions, we both become better equipped to help our startups thrive, which is what our charter goal is as an organization,” states Albert Di Rienzo, President at RedSky.

 

The life sciences industry creates some of the best-paying jobs in the country; however, developing a high-powered, fairly accessible, collaborative platform for launching biotechnology companies is a challenge for this industry, especially in the early-stages of a startup. RedSky has a running start, looking to bridge this siloed space beginning with the Los Angeles bioscience community via LABioHub at ROC Santa Monica. “Building an innovation ecosystem that creates a steady stream of thriving successful enterprises is much more than just putting some clean air hoods in a building. We at RedSky believe the value we bring to our startups has much to do with the valuable introductions we can provide for them. Valuable introductions are a byproduct of the merging of two strong collaborative networks,” points out Neyha Sehgal, Director of Business Development and Market Analysis at RedSky.

 

About RedSky

RedSky is a healthcare innovation incubator and accelerator, created to drive economic growth in the Paso del Norte region and beyond. Established in 2013, RedSky is a touch point for inventors, startups, and academics who have a creative spirit and passion for improving human health. RedSky provides comprehensive funding; scientific, technology, and management expertise; state-of-the-art, purpose-built biomedical labs and office space for startups and on-going concerns; and access to a large network of successful innovators, business leaders, academics, funders, and collaborators. RedSky explores new frontiers in healthcare excellence, ensuring radical new levels of patient care and clinical outcomes are realized for everyone, everywhere. For more information on RedSky, please visit www.RedSkyTX.com.

 

About LABioHub

LABioHub is a cooperative effort among private industry biotech and biomed veteran entrepreneurs, scientists, co-working spaces, accelerators, local life science venture funds, grant writers, patent counsel, legal guidance, financial forecasting tools, social media outlets and capital raising assistance providers.  The mission is to grow the life science industry in Los Angeles stimulating growth of the economy and employment including attracting to and retaining within capital and talent in the region. Fundamental to the latter two missions are LABioHubs efforts to commercialize Los Angeles area developed science, including university and hospital sparked inventions, by creating mutually beneficial partnerships with local industry and supporting innovative entrepreneurs.   LABioHub at this time operates as a subsidiary of Leonhardt Vineyards LLC DBA Leonhardt Ventures and is 45.5 percent owned by Leonhardt Ventures (www.leonhardtventures.com), 45.5 percent by Greenwings Biomedical (www.greenwingsbiomedical.com) and 9 percent by Cal-X Stars Business Accelerator, Inc. (www.calxstars.com). LABioHub recently licensed ROC Santa Monica the rights to open a starter small incubator space at their Santa Monica location which includes LABioHub mentoring and hub support for all firms entering the facility.  This Santa Monica facility has begun accepting applications for startup lab space and mentoring assistance within the 44,000 sq. foot location at 6th and Arizona in Santa Monica (the former Google campus). LABioHub is supported by the 70 person business mentoring team of Leonhardt Ventures’ Cal-X Stars Business Accelerator (http://calxstars.com/team-cal-x/) and its 35 person Scientific Advisory Board comprised of world opinion leaders (http://calxstars.com/scientific-advisory-board/).

New Larger Venue – Leonhardt Ventures & BioLeonhardt Technology Showcase During ACC Chicago April 2nd, 2016

Leonhardt Ventures & BioLeonhardt Technology Showcase During ACC Chicago April 2nd, 2016 – New Larger Venue Notice

Los Angeles, CA, Salt Lake City, UT, Chicago, IL –  March 31st, 2016 – Leonhardt Ventures and BioLeonhardt to Present Technology Showcase in Chicago, IL just outside of American College Cardiology (ACC) Annual Meeting – co-sponsored by HealthiosXchange – Saturday, April, 2nd, 2016 12 noon to 1:30pm @

Conference Chicago at University Center
525 S State St, Chicago, IL 60605
(312) 924-8110

Just over 2 miles from convention center where ACC Annual Mtg is being held at and a short 5 minute walk from the original 37 Van Buren Genosi Apartel location.  Please email hleonhardt@aol.com to RSVP

First combination implantable stem cell/growth factor pump + bioelectric regeneration stimulator for regenerating hearts will be presented – www.bioleonhardt.com + www.myostimpacers.com ;    BioLeonhardt related Scientific Supporting Articles – http://www.bioleonhardt.com/supporting-articles/

Leonhardt Ventures Cal-X Stars Accelerator is led by a 37 person Scientific Advisory Board –  http://calxstars.com/scientific-advisory-board/  and 73 person Business Advisory Board – http://calxstars.com/team-cal-x/

Innovations to be showcased include:

BioLeonhardt  –  http://www.bioleonhardt.com ; – first implantable, programmable, re-fillable stem cell pump in combination with bioelectric regeneration stimulation for treating advanced heart failure.  Featuring combined utilization of MicroRNAs, time release SDF-1, various growth factors, nutrient hydrogel, cardiac matrix, follistatin, tropinelastin, HGH, HGF, IGF-1, Pyruvate, APO E, Erthropoiten, cardiac stem cells, iPS cells and muscle progenitor stem cells all with programmed repeat deliveries.   Bioelectric stimulator causes release of SDF-1, VEGF, follistatin, tropinelastin, HGF from tissues and controls differentiation. Currently in translational study in 55 pigs transitioning to 20 patient pilot trial in Europe.

MyoStim Pacers – http:/www.myostimpacers.com – world’s first heart failure pacemaker designed to recruit reparative stem cells to damaged and weakened heart tissue.

MyoStim Peripheral – electrical stimulation device for treating critical limb ischemia and diabetic foot ulcers, pain relief –    http://www.myostimpacers.com/microcurrent-stimulators.php –  the Axion device is U.S. FDA 510K market cleared for microcurrent treatments – FDA 510(k) K911814.   Data on 47 clinical patients treated with the Wetling (Leonhardt Ventures collaborator) CE Mark approved wireless microcurrent system for treating diabetic foot ulcers in Germany, Switzerland and Denmark will also be presented and well as an introduction to cominbation microcurrent and stem cell + growth factor micro pump healing bandages.

Note – BioLeonhardt and MyoStim are in the process of merging into one entity BioLeonhardt MyoStim.

Cardiobridge – http://www.cardiobridge.com – Highest flow rate 10FR circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI.  Data on about 30 clinical patients will be presented with exceptional notable improvement in renal function.

Bioheart, Inc.* – http://www.bioheartinc.com – Phase III leader in applying adult muscle stem cells to treat advanced heart failure.  Only cell type known to grow new contractile muscle in the depths of scar tissue.  *Leonhardt Ventures founded Bioheart, Inc. in 1999 but now is only a minority position shareholder.  Bioheart MyoCell in Phase II/III clinical trials beat placebo injections by 95.7 meters in exercise capacity improvement.  84% of Bioheart MyoCell treated patients have improved in at least compared to only 16% of placebo or control patients in clinical studies since 2001.

BioPace – world’s first biological pacemaker made entirely of living cells –   http://www.leonhardtventures.com/biopace.php

CoroStim – world’s first vibrational energy emitting pacemaker that prevents plaque formation and blood clots in high risk coronary arteries, heart chambers, heart valves and devices such as LVADs.

CerebraCell – microcurrent based non-invasive or minimally invasive energy system for brain regeneration.  Also non-invasive cerebral aneurysm repair – http://www.leonhardtventures.com/test.php

AortaCell – http://www.leonhardtventures.com/aortacell.php ;- Method and device to treat aortic aneurysms non-invasively and minimally invasively with devices that deliver focal wireless electrical energy to weakened aortic wall tissue that causes reparative autologous stem cells to home to that chosen treatment location which are then differentiated into smooth muscle thus reinforcing vessel wall strength.  Also a new product developed of 2nd beating heart in aorta.

EndoCell – Method and device for growing new endothelium lining of a damaged artery with a percutaneous needle catheter, endothelial progenitor cells, laser light and biolelectric regeneration energy.

Valvublator – Percutaneous catheter device for de-calcifying, cell sodding and regenerating heart valve leaflets so a patient may keep their own valve instead of getting an artificial implant – www.valvublator.com +  http://www.leonhardtventures.com/valbulator.php  Also tissue engineered heart valves.

HeartScore + NI Medical –  Total Heart Failure Management System, heart failure and cardiovascular genomics, lung water necklace, @ home monitoring, smart phone app and high fidelity noise free ECG analysis – www.heartscore.co + http://heartscore.co/heart-failure-management/ + www.heartgenomics.com + www.vivaquant.com   HeartScore is also getting ready to publish the Top 100 Cardiovascular Innovations of 2015/16 eMagazine as well.

BioLeonhardt Whole Body – Developing whole body regeneration chamber designed to take 30 years off age and add 30 years extension to life (early stage development).

In addition to the above cardiovascular focused startups Leonhardt Ventures and Cal-X Stars Business Accelerator, Inc. is incubating EyeCell (eye) -http://www.leonhardtventures.com/eyecell.php, PancreaCell, RegenaLung, MyoStim Skin, MyoStim ED – erectile dysfunction recovery, Stem Cell Bra (breast www.stemcellbra.com), OrothodontiCell (accelerating teeth movement), DentaCell (dental gums healing) – http://www.leonhardtventures.com/denta-call.php, all utilizing microcurrent energy technology to direct stem cell and growth factor expression based healing.  CancerCell another new spin out just filed a patent pending for bioelectric signaling that causes cell division to stop and halts blood flow to cancer tumors followed by a regeneration program.

About Leonhardt Ventures:  Since 1982 Leonhardt Ventures www.leonhardtventures.com has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 250,000 patients have been treated to date with Leonhardt inventions.  In the 1980’s the group developed market leadership in patented cardiovascular polyurethane balloon catheters including drug, stem cell and radiation delivery systems, electrical stimulation devices for improving blood flow and also turn-key cath labs.  In the 1990s they developed over 20 additional devices including the first commercially successful stent graft for aortic aneurysm repair (TALENT – Taheri-Leonhardt Stent Graft) – SEE VIDEO https://vimeo.com/85232193, the first percutaneous heart valve, intravascular lung catheter, the Pro-Cell intracavity stem cell delivery system and the MyoCath line of stem cell delivery catheters.  Leonhardt patented inventions –   http://patents.justia.com/inventor/howard-j-leonhardt ;-   include the first heart failure pacemaker able to recruit reparative stem cells to damaged heart tissue (MyoStim  Pacers – www.myostimpacers.com).  In 2001 the team led the first in the world non-surgical case of stem cell repair of damaged heart muscle in a human patient with  Bioheart  MyoCell  .  That led to the first Phase II/III double blinded, randomized, placebo controlled trial for muscle stem cells growing new contractile muscle in post heart attack tissue in advanced heart failure patients – results published in the American Heart Journal Bioheart  MyoCell patients 95.7 meters improvement in exercise capacity over placebo (minus 4 meters decline).  The Leonhardt led team at BioPace is preparing to complete the first ever biological pacemaker implantation made entirely of living cells in a human patient within the next 12-18 months.  For more Leonhardt Ventures information – http://www.leonhardtventures.com/about-us.php 1Q 2015 Newsletter and 2014 Annual Report – http://us5.campaign-archive2.com/?u=3a3ec29e83782844c8ac560f9&id=158fdee643

About Cal-X Stars Business Accelerator, Inc www.calxstars.com:  Leonhardt Ventures’ organized the Cal-X Stars Business Accelerator, Inc. www.calxstars.com in 2013 to serve as a 5 year business accelerator for cardiovascular life science and social good impact innovations and startups.   The Cal-X Stars 2015 class portfolio includes 20 regenerative medtech and 15 regenerative economy startups.

About Healthiosxchange:    The HealthiosXchange www.healthioxschange.com is the premiere investment marketplace dedicated exclusively to the global healthcare industry.  Employing crowd funding as the cornerstone of a new paradigm in healthcare investing, the HealthiosXchange offers direct access to the broadest investment opportunities on a “Fee Free, Carry Free” basis in the most trusted online environment.  The HealthiosXchange is an affiliate of Healthios Capital Markets, LLC., a FINRA-regulated broker dealer based in Chicago, with offices in Boston, London, Geneva, and Bangkok.  Healthioxchange is a leader in self directed IRA financings with accredited investors into syndicates led by proven track record industry leaders.
Healthiosxchange is the official listing board for the the Cal-X Stars Business Accelerator, Inc. $15 million offering via 506D part C. This exemption allows general solicitation and up to 2000 accredited investors.  Any potential investor’s accredited status must be verified by a broker, lawyer, accountant or other verifiable means.   Cal-X Stars Business Accelerator is incubating/accelerating by charter 15 cardiovascular and 15 social good impact startup innovations with intention to start auctioning them off to the highest bidders starting May 11th, 2018.   By charter Cal-X Stars Business Accelerator, Inc will not accept any self directed IRA investments that exceed 10% of a person’s IRA total portfolio and we recommend 5% due to the very high risk nature of investing in early stage cardiovascular and social good impact startups such as those incubating within the Cal-X Stars accelerator.   Any potential investor should read all risk factors published in our private placement memorandum.

Contact:   Howard Leonhardt, Leonhardt Ventures, 1531 6th Street, Unit 401, Santa Monica, California, 90401, email:     hleonhardt@aol.com or  howardleonhardt@gmail.com

RELATED LINKS

http://www.myostimpacers.com
http://www.healthiosxchange.com

http://www.heartscore.co

SOURCE Leonhardt Ventures and  BioLeonhardt, 1531 6th Street, Unit 401, Santa Monica, CA + Leonhardt’s Launchpads Utah, 489E 400 South, Salt Lake City, Utah 84111 email:    hleonhardt@aol.com

BioLeonhardt Files Provisional Patent Application For Electrical Stimulation Controlled Release Of Follistatin

Santa Monica, CA and Salt Lake City, Utah , Feb. 16th, 2016 /PRBuzz- BioLeonhardt MyoStimwww.bioleonhardt.com funded by Leonhardt Ventures a developer, manufacturer and marketer of advanced organ regeneration products focused on the heart and limbs has announced the expansion of its intellectual property portfolio. BioLeonhardt MyoStim is incubating within Cal-X Stars Business Accelerator, Inc. The Company has filed a provisional patent application in the U.S. Patent and Trademark Office for inventions relating to bioelectric stimulation controlled release of follistatin a powerful muscle repair and formation promoter. Follistatin-like 1 (FSTL1) is a protein that encourages the growth of healthy cells, contractile muscle tissue and even blood vessels, helping supply the newly created muscle tissue with oxygen and nutrients. This therapy invention was originally designed to reduce or eliminate scarring of the heart following a heart attack and reversing heart failure but may also be applicable to treating other organs suffering of muscle loss or degradation.

Howard J. Leonhardt the Founder and CEO of BioLeonhardt MyoStim and Dr. Jorge Genovese a collaborative researcher from Buenos Aires, Argentina are co-inventors of this product. Howard Leonhardt previously patented a series of electrical stimulation devices and signals for homing stem cells to targeted tissues and the controlled differentiation when required into contractile muscle, even within scar tissue starting back starting back in 2000. Dr. Genovese has been conducting electrical stimulation based regeneration research for over twenty years with numerous published peer reviewed papers.

“Folistatin is a key element in improving our ability to regenerate damaged hearts and limbs as well as other organs. Controlled on demand release from cells in a persons own body is ideal for optimizing and maximizing the powerful capabilities of follistatin to improve heart and limb function. Today’s provisional patent filing is a great step towards helping millions of patients in great need without viable alternatives. The potential uses go well beyond heart and limb regeneration and may be useful for hundreds of applications.” stated Howard J. Leonhardt, Co-Inventor

“Numerous published papers, including a number from our own labs, have documented the powerful ability of follistatin to promote repair and form new muscle when and where needed. Until now there was not a practical, safe and cost effective method of controlled delivery. This invention is designed to solve the missing puzzle piece to reproducibly produce safe results in regenerating not only hearts and limbs but other ailing organs including treating erectile dysfunction.” Stated Dr. Jorge Genovese Co-Inventor

Last year a team led by scientists from Utrecht University in The Netherlands pubished postive heart regeneration results with a patch soaked in Follistatin (FSTL-1) placed on damaged heart tissue in small animals – REFERENCE: http://bit.ly/1MTLC7d. For human use it was determined by our team that longer repeat doses were needed and a natural release from a patients own electrically stimulated cells would lead successful human heart regeneration which led to this invention. Our patent pending signals for follistatin release match more closely with the natural low voltage signals in the human body.

A team from the University of Utah in part led by BioLeonhardt Scientitific Advisory Board Members and collaborative researchers Dr. Jorge Genovese and Dr. Amit Patel working with co-researchers in Rome, Italy published in Cell Transplantation, Vol. 21, pp. 493–503, 2013 – In Situ Electrostimulation Drives a Regenerative Shift in the Zone of Infarcted Myocardium – http://bioleonhardt.com/wp-content/uploads/2013/05/IN-SITU-ES-JG.pdf which included documenting increases in numerous beneficial proteins for heart regeneration with a 3V 10HZ signal. Dr. Jorge Genovese previously led a study – http://www.ncbi.nlm.nih.gov/pubmed/19530028 – Electrostimulated bone marrow human mesenchymal stem cells produce follistatin which utilized very high voltage 10 and 40V signals to cause bone marrow cells in the lab to increase release of follistatin. These high voltages proved impractical for use within the human heart due to their high risk propensity to potentially cause arrthymias. This created the need to discover a lower safer voltage signal that could be used in human hearts that led to this new provisional patent application.

Howard Leonhardt co-inventor of this device previously patented an electrical stimulation device for recruiting stem cells to damaged organs including the heart by causing the release of SDF-1 stromal derived factor-1 on demand working in collaboration with Dr. Juan Chachques of Paris – http://www.google.com/patents/US20050171578. This issued U.S. patent has a separate claim for controlling the differentiation of pluripotent stem cells , recruited or injected from sources of bone marrow, fat and circulating blood, to contractile muscle in the depth of myocardial scar tissue. The stimulation voltages of this Leonhardt Chachques patented device range from 1 mV to about 40 mV in line with natural voltages sent by the brain to tissues to stimulate protein releases for repair and regeneration naturally. In line with the natural signals utilized to form heart tissue during fetal development. In total Howard Leonhardt co-inventor of this provisional patent has over 21 issued U.S. patents related to treating heart and cardiovascular disease with over 100 individual patent claims with dozens more pending or in process – http://patents.justia.com/inventor/howard-j-leonhardt

Howard Leonhardt presented earlier this month their team’s 27 Year Experience with Stem Cell Therapies for Organ Regeneration and highlighted some of the spin out startup techonlogy platforms that have emerged from the original work on heart regeneration which are now also incubating in the Cal-X Stars Business Accelerator and Leonhardt’s Launchpads – http://mysocialgoodnews.com/howard-leonhardt-to-present-27-years-of-experience-with-stem-cell-therapies-at-academy-of-regenerative-practices-winter-conference-and-scientific-seminar/

About BioLeonhardt MyoStim:

BioLeonhardt MyoStim is a developer of products for heart and limb regeneration. Its flagship product for heart regeneration utilizes a micro voltage signal generator the size of a quarter implanted in the abdomen of a patient coupled with a re-fillable micro pump. The regeneration stimulator is programmed to cause stimulated tissues to release on demand control SDF-1 (a stem cell homing signal), VEGF (a blood vessel growth protein), HGF (an arrhythmia inhibitor), Follistatin (a muscle repair and formation promotor), VEGF microRNA PI3K/Ak activity enhancer for cardiac stem cell migration, Tropinelastin (improves elasticity of tissues). The micropump is re-filled at least once a week with MicroRNAs, nutrient hydrogel, adipose derived cells including endothelial progenitor cells, muscle stem cells, follistatin, pyruvate, tropinelastin, cardiac matrix and a cardiomyogenic and angiogenic cocktail of additional growth factors. The pump+stimulator combination is designed to totally regenerate a failing heart over a 36 month course of treatment. A similar combination product is used for limb salvage. BioLeonhardt MyoStim legally operates now during its formative development stage as a technology platform license unit (startup) of Leonhardt Vineyards LLC DBA Leonhardt Ventures operating within the Cal-X Stars Business Accelerator, Inc. and will soon be spun out as a stand alone C corporation when its own financial standing is secure enough. All capital for BioLeonhardt MyoStim (a high risk early stage startup) is raised only through Cal-X Stars Business Accelerator, Inc via 506D Part C – SEE RISK FACTORS HERE > http://calxstars.com/investor-relations/ limited to accredited and sophisticated investors only or Leonhardt Ventures’s own internal funds at this time. Leonhardt Ventures’ Cal-X Stars Business Accelerator is led by over 70 business mentors and team members with substantial industry experience – http://calxstars.com/team-cal-x/ and over 35 scientists and clinicians on our Scientific Advisory Board – http://calxstars.com/scientific-advisory-board/

Contact: BioLeonhardt MyoStim a Cal-X Stars Business Accelerator, Inc. Startup Technology Platform – Media Relations Brian Hardy @ brian@fizzpopmedia.com or Howard Leonhardt @ hleonhardt@aol.com. Web Sites: www.bioleonhardt.com, www.myostimpacers.com, www.calxstars.com, www.leonhardtventures.com

About Leonhardt Ventures: Since 1982 Howard Leonhardt (later registered as Leonhardt Vineyards LLC DBA Leonhardt Ventures 2005) www.leonhardtventures.com has led the development and marketing of devices and biologics for treating cardiovascular and heart disease. In the 1980s they developed leadership in patented cardiovascular compliant balloon catheters, in the 1990’s stent grafts and percutaneous heart valves, in the 2000’s stem cell compositions for heart muscle repair and 2010’s electrical stimulation regenerative devices – http://www.leonhardtventures.com/about-us.php Leonhardt Ventures owns 50.1% of Cal-X Stars Business Accelerator, Inc. formed in 2012 and incorporated in California in 2013 a 5 year business and innovation accelerator for regenerative medtech and regenerative ecnonomy startups www.calxstars.com The above mentioned startups are all startup technology platforms at this time within the accelerator transitioning over 5 years from early stage concepts into full fledged stand alone companies. Cal-X Stars also helps operate Leonhardt’s Launchpads www.leonhardtslaunchpads.com, LABioHub www.labiohub.org, Startup California http://startupcalifornia.org, Cal-X Crowdfund Connect www.calxcrowdfund.com and Cal-Xelerator www.calxelerator.com all focused on launching early stage startups.

1H 2016 Newsletter – 2015 Annual Report Summary

Leonhardt Ventures and Cal-X Stars Business Accelerator
1H 2016 Newsletter  – 2015 Annual Report Summary

Leonhardt Ventures founded 1982*

  • 20+ direct U.S. patents for treating cardiovascular disease & dozens indirect
  • 30 more patents in process or pending. 
  • Leonhardt inventions have treated over 350,000 patients
  • Leonhardt inventions have generated more than $3 billion in revenues
  • 7 Major Direct Product Exits – PolyCath cardiovascular balloon catheters 1990, TALENT stent graft for aneurysm repair 1998, Percutaneous Heart Valve 1999, Pro-Cell Stem Cell Delivery Catheter 1999, MyoCath Stem Cell Delivery Catheter 2005, Bioheart Muscle Stem Cell For Heart Failure IPO 2008.  Lucille’s Cafe of Weston 2013.

Click Here for Leonhardt Ventures Historical Milestones and More Information > http://www.leonhardtventures.com/about-us.php

* Leonhardt Ventures legally operates since 2005 as Leonhardt Vineyards LLC DBA Leonhardt Ventures.  Prior to that was sole proprietorship of Howard J. Leonhardt (HJ Leonhardt & Co.). 

Click here for more information on the Cal-X Stars 5 Year Business Accelerator > www.calxstars.com ;

OUR TEAM > http://calxstars.com/team-cal-x/

OUR SCIENTIFIC ADVISORY BOARD http://calxstars.com/scientific-advisory-board/

Leonhardt Ventures Main Master Web Site http://www.leonhardtventures.com

2016 Portfolio Chart with Valuations – http://leonhardtventures.com/our-companies/#toggle-id-1

Portfolio Valuation Growth 2013 to Present – http://leonhardtventures.com/our-companies/#toggle-id-2

Cardiovascular Regenerative Medtech Portfolio Startups (26) (excluding Bioheart) – 

2013 = $3,000,000

2014 = $34,500,000

2015 = $55,100,000

2016 = $224,700,000

2019 – $13.6 billion Target Goal

Regenerative Economy Portfolio Startups (4) 

2013 = $1,000,000

2014 = $12,000,000

2015 = $38,186,500

2016 = $93,000,000

2019 = $2.4 billion Target Goal

2015 Annual Progress Summary with 1Q 2016 Update Included 

The Leonhardt Venture’s Cal-X Stars Business Accelerator, Inc. FOCUSED Portfolio = 26 Regenerative Medtech Startups and 4 Regenerative Economy Startups

Link to our 2016 Full Portfolio Table With Current Valuations and Target Goal Valuations for 2019 – http://leonhardtventures.com/our-companies/#toggle-id-1

 

Top Regenerative Medtech Portfolio Highlights 2015

  • Completed pilot sheep study for Stem Cell Bra with successful results. 
  • Filed provisional patent application for Follistatin release. 
  • Filed provisional patent application for IGF-1 release.
  • Filed provisional patent application for hair regeneration. 
  • Filed provisional patent application for cancer tumor growth treatment. 
  • Filed provisional patent application for whole body regeneration.
  • Filed provisional patent application for accelerated tooth movement. 
  • Discovered signal for controlled release of Tropoelastin.
  • Built CerebraCell prototype for brain regeneration.
  • Secured micro stimulator supplier partnership with $50 million pre-investment in development of smallest, longest battery life most precise control of signaling micro stimulator known to be developed to date. 
  • Completed partnership development contract with micro pump supplier.
  • Secured $500,000 investment commitment from Fluid Synchrony, Inc.
  • Launched HairCell, KidneyCell, LiverCell, PancreaCell, BladderCell, EarCell.

Top Social Good Impact Portfolio Highlights 2014 & 1st Quarter 2015.

  • The Kindheart Lionheart INSPIRATIONAL WORKS TV Network programs reaches over 3 billion views – www.kindheartlionhearttv.com ;
  • Launched Love Roller Coaster program on California Love Channel on KHLH TV Network. 
  • Created Love Dialogues program on California Love Channel on KHLH TV Network.
  • Created COVERS GREAT SPEECHES program and Channel on KHLH TV Network. 
  • Launched Cal-X 30 SOCIAL GOOD IMPACT FUND with 30 curated stocks supported by registered broker dealer Motif Investing. 
  • Launched LABioHub a life science resource for the Los Angeles community.
  • Launched Leonhardt’s Launchpads Utah an incubator/accelerator focused on regenerative medtech and regenerative economy startups in Salt Lake City, Utah. 

Regenerative Medtech Startups Portfolio  http://leonhardtventures.com/regenerative-medtech/

HIGHLY FOCUSED ON THESE CORE TECHNOLOGIES APPLIED TO DIFFERENT APPLICATIONS:

1.  Bioelectric stimulation supported stem cell based regeneration and controlled protein expression based healing.

2.  Implantable pumps, catheters & sensors.

 

REGENERATIVE MEDTECH

2016 Portfolio of Startups 

http://leonhardtventures.com/our-companies/

HEART AND CARDIOVASCULAR

>  BioLeonhardt  – heart regeneration.

>  AortaCell – aorta regeneration.

>  BioPace – biological pacemaker regeneration.

>  Valvublator – heart valve regeneration.

>  CoroStim – vibrational energy to prevent clots, plaque, calcification.

>  HeartScore – genomics based heart failure management.

>  EndoCell – artery regeneration.

>  MyoStim Peripheral – limb blood flow improvement.

>  LVSens – heart sensors.

>  Cardiobridge – circulating assist pump (note – not LV controlled)

>  Leonhardt-Wetling Peripheral – wireless diabetic foot ulcer treatment.

Brain

>  CerebraCell – brain regeneration.

Cosmetic

> Stem Cell Bra – breast regeneration.

> DentaCell – dental gum regeneration + tooth pulp storage.

>  OrthodontiCell – cuts in half dental brace wearing time

>  MyoStim Skin – skin regeneration.

>  MyoStim ED – erectile dysfunction treatment.

>  HairCell – hair regeneration 

Major Organ Regeneration 

>  EyeCell – eye regeneration.

>  PancreaCell – pancreas regeneration.

>  RegenaLung – lung regeneration.

>  LiverCell – liver regeneration.

> KidneyCell – kidney regeneration.

> EarCell – ear hearing regeneration.

> BladderCell – bladder regeneration

>  BioLeonhardt Whole Body Regeneration – Whole body regeneration.

Cancer Treatment 

>  CancerCell – bioelectric cancer tumor treatment + regeneration.

Note – CerebraCell, RegenaLung, BladderCell, LiverCell, KidneyCell and PancreaCell have the cancer tumor stoppage signals built into their organ specific technology platforms.

1.  BioLeonhardt – www.bioleonhardt.com Implantable stem cell pump + microcurrent regeneration stimulator for heart failure regeneration. 

Heart regeneration and limb salvage applications  – Click Here

2.  MyoStim Peripheral  – microcurrent stimulators + micro pumps for limb salvage/diabetic foot ulcers – www.myostimpacers.com

3.  BioPace – biological pacemaker made of living cells – http://leonhardtventures.com/bio-pace/

4.  Valvublator – heart valve regeneration www.valvublator.comhttp://leonhardtventures.com/valvublator/

5.  AortaCell – aorta regeneration – http://leonhardtventures.com/aortacell/

6.  STEM CELL BRA – breast tissue generation and regeneration – www.stemcellbra.com

7.  CoroStim – world’s first vibrational energy device to prevent plaque, calcification or blood clots from forming in the human body or in blood contact devices – http://leonhardtventures.com/corostim/

8.  EndoCell – artery regeneration  

9.  CerebraCell – brain regeneration http://leonhardtventures.com/cerebracell/. ;

10.  EyeCell – eye regeneration http://leonhardtventures.com/eyecell/. ;

11.  DentaCell –  dental gum regeneration – http://leonhardtventures.com/dentacell/

12.  HeartScore – cardiovascular genetic tests and @ home monitoring for personalized care of heart failure patients.   Publisher of the HeartScore Ranking List of Top 100 Cardiovascular Innovations of the Year.  – www.heartscore.co

14.  Cardiobridge USA – www.cardiobridge.com circulatory assist pump on an aortic catheter for acute decompensating heart failure recovery and limb perfusion for limb salvage. 

15.  OrthodontiCell – Accelerated tooth movement – http://leonhardtventures.com/orthodonticell/

16.  RegenaLung – Lung regeneration – http://leonhardtventures.com/regenalung/

17.  PancreaCell – Pancreas regeneration – http://leonhardtventures.com/pancreacell/

18.  BladderCell – Bladder regeneration – http://leonhardtventures.com/bladdercell/

19.  LiverCell – Liver regeneration – http://leonhardtventures.com/livercell/

20.  KidneyCell – Kidney regeneration – http://leonhardtventures.com/kidneycell/

21.  EarCell – Ear regeneration for hearing recovery – http://leonhardtventures.com/earcell/

22.  MyoStim Skin – Skin regeneration – http://leonhardtventures.com/myostim-skin/

23.  MyoStim ED – Erectile dysfunction recovery – http://leonhardtventures.com/myostimED/

24.  CancerCell – Cancer tumor growth stoppage and followup organ regeneration – http://leonhardtventures.com/cancercell/

25.  LVSens – Left ventricle sensor placed in heart percutaneously. 

26.  BioLeonhardt Whole Body– Whole body regeneration – http://leonhardtventures.com/wholebody/

27. HairCell – Hair regeneration – http://leonhardtventures.com/haircell/

Note – In 2015  we attended over a dozen cardiovascular and stem cell regeneration focused conferences including:  Heart Failure Society of America, ACC, TCT, EuroPCR, LA Heart Failure, World Stem Cell Summit, Regenerative Medicine, San Diego Interventions, San Diego Heart Failure,  JP Morgan Healthcare, VEITH, ISET, VIVA, 30th 31s Annual Interventional Cardiology Snowmass.

Social Good Impact Portfolio – http://leonhardtventures.com/regenerative-economy/

HIGHLY FOCUSED ON THESE CORE COMPETENCIES APPLIED TO DIFFERENT APPLICATIONS:

1.  Crowdfunding.

2.  Social good impact innovations including social good impact media.

1.  The Kindheart Lionheart TV Network www.kindheartlionhearttv.com – INSPIRATIONAL WORKS TV TV network with hundreds of programs, over 3 billion billion views across all programs. 

2.  The California Stock Exchange TM www.calstockexhange.com – on path to be first U.S. social good impact stock exchange.  

> THE CALIFORNIA STOCK EXCHANGE TM FACEBOOK PAGE > https://www.facebook.com/Calstockexchange

3.  Cal-X Stars Business Accelerator, Inc. – regenerative medtech, life science and regenerative economy incubators and accelerators. 

Incubators and Accelerators

HIGHLY FOCUSED ON STARTUP LAUNCHES THESE TWO AREAS:

1.  Regenerative medtech. 

2.  Regenerative economy. 

1.   Cal-X Stars Business Accelerator, Inc. – www.calxstars.com – 5 year accelerator focused on cardiovascular and social good impact innovations – 15 cardiovascular and 15 social good impact startups being accelerated in current class.

2.  Cal-Xelerator – www.calxelerator.com – 15.5 week (108 days create to great) startup launch accelerator focused on cardiovascular + social good impact including social good media/

Cal-Xelerator Application – Click Here

3.  Leonhardt’s Launchpads @ UNC STIC – www.leonhardtslaunchpads.com – incubator + accelerator for life science startups located at the University of Northern California Science & Technology Center in Rohnert Park, California (near Santa Rosa) – www.uncm.edu – Howard Leonhardt has served on the Board of Directors of the University of Northern California since 2000 helped lead the launch their incubator program in 2007 – BOARD http://www.uncm.edu/About_BoardDirectors.php + Incubated Companies  http://www.uncm.edu/STIC_CoSpinoffs.php + PRESS DEMOCRAT ARTICLE ON INCUBATOR – http://www.pressdemocrat.com/news/2252451-181/howard-leonhardt-will-help-other

4.  LABioHub – www.labiohub.org – a life science incubator and resource hub in Santa Monica.  PRESS RELEASE and BIOSPACE News Coverage > http://www.biospace.com/News/labiohub-roc-santa-monica-taking-applications-for/364990

5. Startup California – http://startupcalifornia.org – resources for California startups. 

6.  Leonhardt’s Launchpads Utah – regenerative medtech and economy incubator/accelerator located in Salt Lake City, Utah.

7. SciAccelerator – Science and technology startup accelerator under development with a crowdfunding campaign building focus. 

8.  Leonhardt’s Launchpads Georgia – Setting up just off the campus of the University of Georgia near Atlanta and coordinating collaborative research all over the southeastern USA. 

 

“In the modern age, whether we like it or not, all companies are media companies. No matter how great a product you have if the story doesn’t get heard by the people who need to hear it, it doesn’t get traction and off the ground. There’s no better place at crafting stories in the modern media world than Los Angeles.”  Howard Leonhardt as quoted in The Huffington Post

PATENTS & TRADEMARKS  – Leonhardt +

 

Recent Press

REGENERATIVE MEDTECH STARTUPS 2016 PORTFOLIO UPDATES

 

MyoStim Peripheral . – limb regeneration. 

www.myotimpacers.com

  • Secured manufacturing partner in Los Angeles area
  • Recruited Joel Hirsch, past-President of Alfred Mann’s Core Manufacturing to lead the manufacturing of these heart repairing pacemakers in Los Angeles.
  • Recruited Suresh Gurunathan former Director of Engineering at NanoStim to serve as Senior Advisor Pacer Engineering.  
  • Recruited Jane Reedy former Director of Clinical Affairs for Thoratec and HeartWare to serve as Senior Advisor Clinical Affairs.
  • Designed progressive aggressive limb salvage protocol.

BioLeonhardt MyoStim www.bioleonhardt.com – Implantable, programmable, re-fillable stem cell & growth factor pump combined with electrical stimulation for damaged heart muscle regeneration and limb salvage.

  • Developed world’s smallest micro stimulator with longest battery life and most precise control of electrical signals working with QIG Greatbatch.  Over $50 million invested into this development. 
  • Filed patents for IGF-1, Follistatin, Tropoelastin, eNOS, Activin, HGF signals to add to portfolio.
  • Our micro pump partner secured over $2 million in SBIR research grants. 
  • Developed protocol for translational studies for heart regeneration.
  • Met with FDA about Category B designation for $58,000 reimbursement per clinical case completed in the USA. 
  • Sourced infusion pacing leads with corkscrew tip.
  • Began development of wireless energy transmission ver. 2.0. 

 

Stem Cell Bra www.stemcellbra.com – World’s first women’s bra with built in electrical stimulation homing signal for stem cells with ability to differentiate them into breast tissue.  

  • Completed pilot large animal study in Argentina with positive results. 
  • Developed working prototypes.
  • Filed two provisional patent applications.
  • Solidified research alliance with Dr. Joel Aronowitz of Cedars Sinai UCLA.
  • Initiated large animal study in Argentina with Dr. Jorge Genovese. 
  • Add dozens of supporting papers to web site.

Valvublatorhttp://www.leonhardtventures.com/valbulator.php  + www.valvublator.com – first catheter based device for decalcifying, cell sodding, surface modifying and microcurrent regenerating heart valves so a patient may keep their own heart valve instead of getting an implant.

  • Prepared a provisional patent application ready to be filed.
  • Developed research collaboration with Dr. Mark Cunningham, Chief of Staff Cardiac Surgery at USC Keck Medical Center.
  • Developed protocol for preserving a patients own heart valve without surgery.
  • Presented Valvublator at 31st Annual Interventional Cardiology Meeting in Colorado.
  • See www.valvublator.com for supporting science slide deck. 

LV Sens – Left ventricle heart sensor placed via catheter

  • Prepared provisional patent application for catheter based delivery.
  • Developed disolvable cone design for percutaneous placement.

EndoCell – Endothelial progenitor cells delivered via adventia tissue micro needle catheter combined with microcurrrent stimulation for healing damaged arteries

  • Developed research alliance with Dr. Warren Sherman, Director of Cardiovascular Stem Cell Research Columbia University and Dr. Dayu Teng University of California San Diego. 
  • Secured contract supplier for adventia needle catheter – Mercator Medical Systems.
  • Secured manufacturing partner for micro stimulator. 
  • Developed pre-clinical and clinical study plan.

AortaCell – Non-invasive wireless energy device for healing aortic aneurysms, strengthening aortic necks in stent graft cases and sealing Type III endoleaks non-invasively.

  • Developed manufacturing partner for micro stimulator.
  • Recruited Dr. Juan Parodi to research team.
  • Recruited Dr. Harrison Lazarus to research team.
  • Designed catheter based system.
  • Designed protocol for reinforcing aortic necks to improve stent graft performance.
  • Designed protocol for creating a beating 2nd heart aorta. 
  • Granted 4% of seed stage equity to research and kids funds on behalf of co-Founder Dr. Roy Greenberg, former Chief of Vascular Surgery of Cleveland Clinic that passed away last year at age 49 of cancer. 

DentaCell –   – Microcurrent devices for healing dental gums, teeth and jaw bone.

  • Secured manufacturing partner for micro stimulator. 
  • Established registered tooth pulp storage service partnership for future stem cell expansion in case of need.

OrthodontiCell – Tooth Movement Accelerator – designed to cut in half dental brace and aligner wearing time. 

  • Filed provisional patent application.
  • Designed prototype. 
  • Recruited Dr. John Marchetto to serve as President. 

CerebraCell –   – Microcurrent device for helping patients recover from brain trauma and strokes. 

  • Discovered signal for controlled expression of IGF-1 and filed provisional patent. 
  • Secured manufacturing partners.
  • Add dozens of supporting papers to web site. 
  • Prepared provisional patent application ready for filing.
  • Secured investment from the University of Northern California Foundation.
  • Placed CerebraCell in Leonhardt’s Launchpads @ UNC STIC Incubator near Santa Rosa, CA. 
  • Recruited Dr. Santosh Kesari noted Cerobrovascular Researcher and Brain Surgeon to team. 

 

EyeCell –  http://www.leonhardtventures.com/eyecell.php – Microcurrent device for reversing macular Degeneration and for treating other eye disorders.

  • Lined up manufacturing partners.
  • Partnered with renowned eye surgeon Dr. Patrick Johnson of Minneapolis.
  • Recruited Dr. Edward Kondrot renowned expert of microcurrent eye related therapies to research team.
  • Placed EyeCell duly in Cal-X Stars and Leonhardt’s Launchpads at UNC STIC incubators in Santa Monica and Santa Rosa. 

 

CoroStim – Vibrational energy device for preventing plaque, calcification and clot formation in human bodies and blood contact devices. 

  • Prepared provisional patent application for filing.
  • Lined up manufacturing partners.
  • Conducted market research.
  • Found and posted dozens of supporting papers. 

BioPacehttp://www.leonhardtventures.com/biopace.php – Biological pacemaker made of living cells placed via a percutaneous needle tipped catheter.

  • 2 patents issued.
  • Held research collaboration discussions with European investigators. 

 

HeartScore www.heartscore.co – Full lineup of cardiovascular diagnostics including genetic tests and @ home and point of care monitoring for developing individualized care for heart failure and cardiovascular patients.

  • Developed Heart Failure Management Program. 

Cardiobridgewww.cardiobridge.com  – circulatory assist pump on catheter. 

  • Held experts panel meeting @ ACC Chicago to design clinical plan.
  • Developed animation video.
  • Prepared regulatory plan
  • Developed reimbursement strategy.
  • Recruited Dr. Leslie Miller to team. 
  • Filed for CE Mark approval. 
  • Presented data on 35 patients at EuroPCR and other meetings. 

PancreaCell – pancreas regeneration

  • Developed manufacturing partnership for micro stimulator.
  • Developed manufacturing partnership for micro pump.
  • Met with University of Georgia Incubator based potential collaborators.
  • Recruited Dr. Camillo Ricordi of Miami Diabetes Research Institute as an advisor.
  • Assembled large number of supporting scientific articles.
  • Recruited Dr. Nicholas Chronos as an advisor

BladderCell

  • Developed manufacturing partnership for micro stimulator.
  • Developed manufacturing partnership for micro pump
  • Recruited Laurelle Johson as an advisor.

RegenaLun

  • Developed manufacturing partnership for micro stimulator.
  • Developed manufacturing partnership for micro pump. 

KidneyCell

  • Developed manufacturing partnership for micro stimulator.
  • Developed manufacturing partnership for micro pump

LiverCell

  • Developed manufacturing partnership for micro stimulator.
  • Developed manufacturing partnership for micro pump.

EarCell

  • Developed manufacturing partnership for micro stimulator.
  • Developed manufacturing partnership for micro pump

HairCell

  • Developed manufacturing partnership for micro stimulator.
  • Developed manufacturing partnership for micro pump.
  • Secured manufacturing partner for head helmets. 
  • Recruited Derek Kahn to serve as President.
  • Designed clinical protocol and pre-clinical plan. 
  • Files provisional patent applications for follistatin and IGF-1. 
  • Building and testing prototypes in Utah @ Leonhardt’s Launchpads Utah. 
  • Developing working relationship with the University of Northern California. 

MyoStim ED

  • Developed manufacturing partnership for micro stimulator.
  • Developed manufacturing partnership for micro pump.
  • Lauched beta web site. 

MyoStim Skin

  • Developed manufacturing partnership for micro stimulator.
  • Developed manufacturing partnership for micro pump.
  • Developed relationship with Dr. Leif Rogers in Beverly Hills, CA for clinical studies. 

 

Regenerative Economy Portfolio Updates 

 

The California Stock Exchangewww.calstockexchange.com – Aspirations to become 1st U.S. social good impact stock exchange  – under development.

  • Secured registered Trademark for The California Stock Exchange TM.
  • Launched Cal-X 30 Social Good Impact Index Fund/Exchange Traded Fund powered by Motif Investing a registered broker dealer. 

The Lions Den TV Show Cal-Xhttp://www.calstockexchange.com/the-lions-den/  – Launched online crowdfunding TV show airingon The Kindheart Lionheart INSPIRATIONAL WORKS TV Network – www.kindheartlionhearttv.com ;

Cal-X Crowdfund Connect – www.calxcrowdfund.com – Crowdfunding campaign building services firm launched.  

Cal-X Stars Business Accelerator, Inc. – www.calxstars.com – 5 year business accelerator specializing in cardiovascular and social good media innovations.

  • Accelerated progress of 26 regenerative medtech and 4 regenerative economy startups. 
  • Secured 80 business advisors with substantial experience.
  • Secured 37 scientific and clinical advisors with substantial experience.

Cal-Xelerator www.calxelerator.com – 108 day startup launch accelerator.

  • Developed and published comprehensive 15 1/2 week program for startup launch

Leonhardt’s Launchpads NorCal  www.leonhardtslaunchpads.com – Incubator for select few life science companies at University of Northern California Science & Technology Innovation Center.

  • Sapheon Medical that incubated at UNC STIC sold for $238 million to Medtronic Covidien. 
  • Enrolled EyeCell and CerebraCell in Leonhardt’s Launchpads @ UNC STIC at the University of Northern California in Rohnert Park, California (near Santa Rosa 45 minutes north of San Francisco)

Food Trikes and Scooters www.foodtrikesandscooters.com – Solar powered mini food trucks supported by full array of services.

  • Built out and sold first unit.  
  • Developed sales brochure and web site.
  • Secured manufacturing partnerships.  

Wine Country Baseball www.winecountrybaseball.com  + http://www.leonhardtventures.com/wine-country-baseball.php – Development league for showcasing players hoping to get signed to MLB contracts.

  • Preparing for 7th Annual Wine Country Baseball Classic. 

Cal-Xporthttp://cal-xport.com/  – The “Alibaba” site for California exporters.

  • Launched web site.
  • Promoted UCLA export education programs.
  • Developed TRIP MATCHING SERVICE to help exporting companies make overseas export sales calls at less expense.  Working on developing easy to use APP. 
  • Posted dozens of helpful resource links.

Kindheart Lionheart Media & Publishing www.kindheartlionheart.com – Online book store – inspirational works. Publisher, creator and producer of inspirational content.

  • Advanced forward Dolphin Smiles: The Legend of Kindheart LIonheart via UCLA Writing Program.

Kindheart Lionheart TV Network www.kindheartlionhearttv.com – Inspirational works TV network.

  • Selected programs have more than 2 billion views. 
  • Created 4 original in-house original programs.

Kindheart Lionheart Startup Media Support Services  http://kindheartlionheart.com/startup-media-support-services/ – Media marketing and ad team to help launching startups.  We take part cash and part equity for pay for services.  Primarily producer of company videos.

  • Developed full service studio for producing TV shows, ads, music videos, company videos and short films. 

Radio Veronica USAwww.radioveronicausa.com – Online radio station set up to crowdfund the publishing rights of songs with one tap of your phone.

  • Launched first Facebook based radio station that allows listeners to crowdfund purchase publishing rights of songs. 

The Kindheart Lionheart Radio Showhttp://www.leonhardtventures.com/khlh-radio.php – Radio show focused on stories of compassion and courage in the marketplace in the era of conscious capitalism.

  • Aired 14 episodes covering stories of compassion and courage in the marketplace, innovators and creators. 

Kindheart Lionheart Adventureswww.lionheartadventures.com – Charitable giving travel company and set of products to help foundations raise funds.

  • Arranged over 24 exciting charitable giving and foundation fund raising adventure pacakages.

Startup California www.startupcalifornia.org –  Startup support services.

  • Over 100 interns signed up into summer startup internship program.
  • Upgraded the Startup Jobs site.
  • Managed 8 state regions.
  • Posted over 4000 posts of information helpful to startups.

LA BioHubwww.labiohub.org –  Life science information hub with plans for a physical incubator in near future for the Los Angeles area.

Lucille’s Cafes Franchising & Licensing Co. http://www.leonhardtventures.com/lucilles-cafe.php + www.lucillescafes.com – Holding company that holds trademark, franchising, SOPs and recipe rights for the highly successful Lucille’s Cafes.

  • Completed franchise package for restaurant.
  • Designed Lucille’s on Wheels Food Truck.
  • Developed Lucille’s on Wheels full menu.
  • Developed Lucille’s on Wheel’s Mini Food Truck design.
  • Developed Lucille’s on Wheel’s Food Trike design.

Entrepreneurship Party Public Policy Institutewww.entrepreneurshipparty.com – Public policy institute to support entrepreneurs.

2016 Priority List – Goals

HEART AND CARDIOVASCULAR

>  BioLeonhardt  – heart regeneration.

1.  Finish large animal studies in Spain.

2.  Prepare to launch clinical trials in 2017.

3.  Continue to build patent estate.

>  AortaCell – aorta regeneration.

1.  Finish large animal studies at LABioMed Harbor UCLA.

2.  Initiate pilot OUS clinical studies. 

>  BioPace – biological pacemaker regeneration.

1.  Initiate animal studies with University of Rostock.

>  Valvublator – heart valve regeneration.

1.  Finalize prototypes at University of Utah.

2.  Complete large animal studies. 

3.  Prepare to launch clinical studies in 2017.

>  CoroStim – vibrational energy to prevent clots, plaque, calcification.

1.  Finalize prototypes and lab testing. 

2.  Complete large animal studies. 

3.  Build patent estate. 

>  HeartScore – genomics based heart failure management.

1.  Launch in North American market. 

>  EndoCell – artery regeneration.

1.  Complete translational studies in Italy with Dr. Antonio Colombo with guidance from Dr. Warren Sherman and Dr. Dayu Teng.

>  MyoStim Peripheral – limb blood flow improvement.

>  Initiated progressive aggressive limb salvage trial in Czech Republic. 

>  LVSens – heart sensors.

>  Build and lab test prototypes in Los Angeles and Utah. 

>  Cardiobridge – circulating assist pump (note – not LV controlled)

>  File for 510K for high risk PCI in USA.

>  File for CE Mark in Europe.

>  File to begin heart failure clinical trials in the USA.

>  Leonhardt-Wetling Peripheral – wireless diabetic foot ulcer treatment.

>  File for 510K in USA.

>  Initiated Phase II/III controlled study in the USA. 

Brain

>  CerebraCell – brain regeneration.

>  Complete tumorgenecity animal studies in Cleveland, Ohio.

>  Launch OUS pilot clinical trial for stroke recovery.

>  Launch OUS pilot clinical trial for cancer tumor stoppage.

>  Launch OUS pilot clinical trial for cerebral aneurysm repair. 

Cosmetic

> Stem Cell Bra – breast regeneration.

>  Finalize sheep study in Argentina.

>  Prepare for pilot OUS clinical trials. 

> DentaCell – dental gum regeneration + tooth pulp storage.

>  Launch tooth pulp storage program in USA.

>  Complete study for pain relief in healing.

>  OrthodontiCell – cuts in half dental brace wearing time

>  Complete large animal studies in Argentina.

>  Launch pilot clinical trial OUS.

>  MyoStim Skin – skin regeneration.

>  Launch pilot clinical trial with Dr. Leif Rogers in Los Angeles. 

>  MyoStim ED – erectile dysfunction treatment.

>  Complete pre-clinical studies with Dr. Nestor Ca-David Gonzalez at LABioMed Harbor UCLA.

>  HairCell – hair regeneration 

>  Complete tumorgencity studies.

>  Launch pilot OUS clinical trial. 

Major Organ Regeneration 

>  EyeCell – eye regeneration.

>  Complete registry study for microcurrent macular degeneration recovery.

>  Launch OUS cornea regeneration study.

>  PancreaCell – pancreas regeneration.

>  Complete cadaver studies at U of Miami with Dr. Camillo Ricordi.

>  Complete large animal studies at U of Georgia with Dr. Nic Chronos.

>  Launch OUS pilot clinical trial in China, Italy and Canada. 

>  RegenaLung – lung regeneration

>  Complete pre-clinical studies.

>  Prepare for OUS pilot clinical trial.

>  LiverCell – liver regeneration.

>  Design final protocol and product.

> KidneyCell – kidney regeneration.

>  Design final protocol and product.

> EarCell – ear hearing regeneration.

>  Deisgn final protocol and producdt.

> BladderCell – bladder regeneration

>  Design final protocol and product. 

>  BioLeonhardt Whole Body Regeneration – Whole body regeneration.

> Find a development partner for this project. 

Cancer Treatment 

>  CancerCell – bioelectric cancer tumor treatment + regeneration.

Note – CerebraCell, RegenaLung, BladderCell, LiverCell, KidneyCell and PancreaCell have the cancer tumor stoppage signals built into their organ specific technology platforms.

>  Complete lab studies.

>  Launch pre-clinical studies.

>  Prepare for 2017 pilot clinical trials. 

Regenerative Economy

>  The California Stock Exchange TM

>  Get more press coverage.  

>  Recruit big names to join us.

>  Increase promotion of iDISCLOSE PPM product sold on commission basis.

>  Increase promotion of WorthWorm pre-money valuation software on commission basis. 

>  Fine tune the Cal-X 30 Social Good Impact Fund after 1 full year of experience.

>  Prepare for stock exchange regulatory filings with a partner.

>  Cal-X Crowdfund Connect

>  Focus on $15K paid crowdfunding marketing assistance campaigns. 

>  Food Trikes and Scooters

>  Hire a sales manager to boost sales. 

> Wine Country Baseball

>  Hold 7th Annual Wine Country Baseball Classic September 29th.

>  Cal-Xport

>  Upgrade web site tools for exporters.

>  Kindheart Lionheart Media & Publishing

>  Get Dolphin Smiles:  The Legend of Kindheart Lionheart published or self publish it.  Send screenplay out to all major studios.

>  Kindheart Lionheart TV Network

>  Film new episodes of Love Roller Coaster.

>  Film California Love series.

>  Film Covers of Great Speeches series.

>  Film Lions Den Startup Pitch Crowdfunding Show. 

>  Film Love Dialogues series.

>  Surpass 3.5 billion views across all programs.

>  Hire advertising sales manager. 

>  Radio Veronica USA

>  Promote crowdfund purchase of portion of publishing rights of songs product.

>  Kindheart Lionheart Adventures

>  Develop a poster and online ad that travel agencies can display.

>  Partner with a major travel agency. 

>  Lucilles’ Cafe’s of America

>  Sell franchises. 

>  Leonhardt’s Launchpads Utah

>  Get lab set up at BioInnovations Gateway.

>  Hire 3 biomedical engineers.

>  Integrate with U of Utah researchers.

>  File for multiple SBIR grants.

Leonhardt’s Launchpads NorCal

>  Support CerebraCell.

>  Support EyeCell.

>  Reorganize Tisugen Therapeutics.

>  Reach out to recruit more local startups.

>  Develop certificate programs in bioengineering modeled after UCLA Extension programs. 

Leonhardt’s Launchpads Georgia

>  Get small office set up at U of Georgia Innovations Gateway supported by a local intern and Dr. Nic Chronos to start at low cost. 

Cal-Xelerator

>  Recruit 4 exciting outside startups to join 108 day startup launch bootcamp.

LABioHub

>  Hold a Santa Monica based Life Science startup pitch contest.  Enter our own companies and use truly independent judges.

Startup California

>  Hold crowdfunding and startup finance seminars in San Diego, OC, LA, Santa Barbara, San Jose, San Francisco, Santa Rosa, Sacramento and Lake Tahoe.  Sell iDISCLOSE, Cal-X Crowdfund Connect and WorthWorm as sponsors. 

Cal-X Stars Business Accelerator, Inc.

>  Focus on advancing the current 2016 portfolio with patents, supporting data, opinion leader endorsements and positive press.  Build excitement in financial community. 

>  Work on getting blog coverage for our startups. 

>  Recruit Chief Medical Advisors and CEOs for each startup not yet staffed.

>  Help all incubating/accelerating startups pursue SBIR grants. 

 

Leonhardt Ventures World Medical

“There is something Special About this Team!” Corporate Video

CLICK HERE

 

The California Stock Exchange TM Announces Progress and Long Term Plan

Santa Monica, CA – June 12th, 2015 – Today Leonhardt Ventures announced its progress in developing Cal-X The California Stock Exchange TM intended to be first social good impact stock exchange in the USA.

“Treating people and community well with a strong sense of purpose and a vibrant innovation culture is not just good for good sake, it is simply good business.” Howard J. Leonhardt Chairman and Founder The California Stock Exchange TM

“Companies that treat people well and have a sense of purpose recruit, retain and motivate the best people. People that believe in the work they are doing and are energized everyday. This leads to innovation and happy repeat customers and higher returns to investors.” Leonhardt further states. “People that believe in this principle will now have a dedicated marketplace.”

Cal-X is being developed by a 70 person all star team of experienced industry veterans that Leonhardt has recruited to help guide all developments – http://calxstars.com/team-cal-x/

“We are 2 years into our original 5 year plan and we have made great progress.” Leonhardt points out. These Cal-X units have already launched…

Cal-X Stars 5 Year Business Accelerator, Inc. www.calxstars.com – A 5 year business accelerator with a social good impact focus has enrolled 30 outstanding startups with seed funding and great progress achieved. 15 startups are developing breakthrough cardiovascular innovations primarily stem cell based and 15 are social good impact innovations with a strong crowdfunding component to them. The portfolio has increased $70 million in valuation since 2013 – http://us5.campaign-archive2.com/?u=3a3ec29e83782844c8ac560f9&id=158fdee643

Cal-Xelerator www.calxelerator.com – 108 day “create to great” startup launch accelerator for social good impact startups based in Santa Monica.

Cal-X Crowdfund Connect – www.calxcrowdfund.com – crowdfund campaign builder for social good impact cos. Featuring curated specialty portals.

Cal-X Microloans – http://www.calstockexchange.com/calx-microloan-program/ – microfinancing guidance for social good impact enterprises via partnerships.

Cal-X Funders Club Syndicate – http://www.calstockexchange.com/cal-x-funders-club/ – enables accredited angels to invest side by side with social good impact investing pros. 1st Syndicate led listing is on HealthiosXchange – www.healthiosxchange.com under Cal-X Stars.

Cal-X Coffee Shops – http://www.calstockexchange.com/cal-x-coffee-shops/ – designated gathering spots for informal networking with other social good impact investors and startups.

Cal-Xport – www.cal-xport.com – The “Alibaba” site for matching foreign buyers with California exporters. Other helpful aides for California startups seeking to export. Exports creates jobs! Features Trip Matching Service matching people that want to travel to foreign locations with small California firms seeking an export rep to make sales calls for them.

calxstarsproducts 1434092527

CrowdImpact – Working with www.Crowdfunder.com we helped launch CrowdImpact a Social Enterprise Pitch Contest with donation prize money from Cal-X Crowdfund Connect – VIDEO > https://www.youtube.com/watch?v=RKCXMk6OI8c

The LIONS DEN Online Startup Pitch TV Show – http://www.calstockexchange.com/the-lions-den/ – Startups pitch to not only a panel of judges in studio but to audience viewing on TV. With proper registrations audience viewers can invest in companies pitching on the show  http://www.crowdfundinsider.com/2014/03/33008-cal-x-lions-den-seeks-applicants-online-tv-pitch-contest/ LIONS DEN will initially air on The Kindheart Lionheart INSPIRATIONAL WORKS TV Network www.kindheartlionhearttv.com

The next Cal-X innovation launches coming soon…

Cal-X 30 Index Fund – Curated basket of 30 social good impact stocks currently listed on NASDAQ and other exchanges sold as a package to attempt to reduce risk. Set to launch by the end of this year. Our simple goal year 1 = BEAT THE DOW 30. During the initial test period for this index fund we do not intend to invite outside investors in until after we prove out the model, which may require some adjustments from the original test group.

Cal-X BDC Fund – Business Development Corp. fund to fund private and public social good impact high growth companies. Following this model – https://www.wrhambrecht.com/wp-content/uploads/poliwogg/poliwogg-road-show-presentation.pdf

Cal-X OTC – A social good impact curated selection of OTC Markets stocks assembled into an index fund.

Cal-X Venture Exchange – A listing board for research tested post crowdfunded social good impact stocks. An eBay or Craigslist of sorts for Reg A stocks that wish to be sold private buyer to private buyer.

Cal-X The California Stock Exchange TM – Plans to be a full fledged stock exchange competing with NASDAQ and NYSE that only lists highly selected social good impact stocks. We will launch this after proving out the profitability of the Cal-X 30 Index Fund. Proper registration as a full fledged stock exchange or an alternative trading system will require significant investment of resources over time.

calxstarsportfolio1434092527

Crowdfund Insider recently published an excellent story on The California Stock Exchange TM –http://www.crowdfundinsider.com/2013/03/12225-california-stock-exchange-crowdfunding/

INC. Magazine broke the Cal-X story first in 2012 with a bold attention grabbing headline article STARTUP TO CREATE 23 MILLION JOBS – http://www.inc.com/nicole-carter/start-up-to-create-23-million-jobs.html

The California Stock Exchange TM – Introduction videos:

(1) In Person – https://www.youtube.com/watch?v=NyHU5j-94Lk

(2) Animation – https://www.youtube.com/watch?v=Zx5bpw3dm9Y

“Social good impact stock exchanges have already launched in Europe, Asia and Canada. It is about time one launches in the USA. We have been studying carefully the best practices of these great innovators to help improve the design of Cal-X The California Stock Exchange TM” Leonhardt further states.

Here are links to more information on the social stock exchanges in Europe, Asia and Canada.

Asia – Impact Investment Exchange TM – http://www.asiaiix.com/   http://impactexchange.asiaiix.com/

Europe – Social Stock Exchange TM – http://socialstockexchange.com/

Canada – The SVX formerly the Social Venture Exchange TM – http://impactinvesting.marsdd.com/strategic-initiatives/svx-formerly-the-social-venture-exchange/

Here is a link to a great article in The Stanford Social Innovation Review…

The Rise of Social Stock Exchanges January 8th, 2015 http://www.ssireview.org/blog/entry/the_rise_of_social_stock_exchanges

Additional information on all Leonhardt Ventures and Cal-X Stars Business Accelerator, Inc. developments may be found in their latest 1Q 2015 Newsletter – http://us5.campaign-archive2.com/?u=3a3ec29e83782844c8ac560f9&id=158fdee643

A video of Cal-X founder Howard Leonhardt explaining the spirit of The California Stock Exchange TM at the 2014 Heart Centered Tech Leadership Conference may be found via this YouTube link – https://www.youtube.com/watch?v=XyOYs7jQico

 

> CROWDFUNDING INDUSTRY SPOTLIGHT ON HOWARD LEONHARDT > http://www.crowdfunding.biz/blogs/1/70/crowdfunding-industry-spotlight-5-howard-leonhardt

> Leonhardt speaking at DEBATE ON CROWDFUNDING, BERKELEY, CA – https://www.youtube.com/watch?v=E_giNK4gYqs

About Leonhardt Ventures www.leonhardtventures.com: Founded in 1982 Howard J. Leonhardt and operating now since 2005 as Leonhardt Vineyards LLC DBA Leonhardt Ventures. Leonhardt Ventures from 1982 to 2008 specialized only in developing innovations for treating heart and cardiovascular disease. In the 1980’s they patented and led the development of the world’s leading polyurethane balloon cardiovascular catheters as well as the first intravascular lung catheter and radiation delivery systems. In the 1990’s they developed the first commercially successful stent grafts for repairing aortic aneurysms without surgery as well as the first percutaneous heart valve, biological pacemaker and stem cell delivery catheters. In the 2000’s they led the team that completed the first-in-man non-surgical stem cell repair of a damaged heart. Since 2010 the team has pioneered the development of microcurrent technologies for directing stem cell regeneration of organs and tissues as well as the first implantable stem cell pump. Leonhardt holds over 21 patents with dozens more in process or pending and has licensed over 40 more. Over 250,000 patients have been treated to date with Leonhardt inventions generating more than $3 billion in revenues. In 2008 Leonhardt Ventures opened a new sector of innovation development under the banner social good impact and has launched since then 15 social good impact innovation startups most with a strong crowdfunding component to them. This includes The Kindheart Lionheart INSPIRATIONAL WORKS TV Network www.kindheartlionhearttv.com. Leonhardt Ventures is moving slowly and cautiously in building Cal-X The California Stock ExchangeTM and all its units to ensure compliance with all regulations and to make sure the products are tested before opening them up to outsiders. Cal-X is primarily an information source at this time for those interested in social good impact investing and for social good impact startups seeking to grow.